TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

Group 1: Teva's New Drug Development - Teva Pharmaceutical Industries Limited has initiated IND-enabling studies on BD9, a dual-specific multibody targeting TSLP and IL-13 for treating TH2-driven inflammatory diseases like asthma and atopic dermatitis [1][2] - Teva holds an exclusive license to develop BD9, which aims to block IL-13 and TSLP, key drivers of TH2-driven inflammation, potentially improving patient outcomes [2] - Teva is responsible for the global development of BD9, while Biolojic Design Ltd. will receive regulatory and commercial milestone payments [3] Group 2: Financial Performance and Market Reaction - Following the announcement of BD9, Teva's shares increased by 4.4% on May 27, although the company has seen a year-to-date decline of 19.6%, compared to the industry's decline of 15.8% [3] - Teva currently holds a Zacks Rank of 3 (Hold) [6] Group 3: FDA Fast Track Designation - The FDA has granted Fast Track designation to Teva's anti-IL-15 antibody, TEV-53408, for treating celiac disease on a gluten-free diet, aimed at expediting the development and review process for serious conditions [4] - A phase IIa study is evaluating the safety and efficacy of TEV-53408 for adults with celiac disease, indicating progress in Teva's innovative pipeline, particularly in neuroscience and immunology [5]